Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis
JAMA · 25.02.2025 · 333 (8) · 682
DOI: 10.1001/jama.2024.26458 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 25.02.2025. Verfasst von Paul Dark und 32 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Critical Care Unit, Northern Care Alliance NHS Foun…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, C-Reactive Protein, Procalcitonin, Sepsis. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Sepsis
Abstract (Originalsprache)
Importance For hospitalized critically ill adults with suspected sepsis, procalcitonin (PCT) and C-reactive protein (CRP) monitoring protocols can guide the duration of antibiotic therapy, but the evidence of the effect and safety of these protocols remains uncertain.
Objective
To determine whether decisions based on assessment of CRP or PCT safely results in a reduction in the duration of antibiotic therapy. Design, Setting, and Participants A multicenter, intervention-concealed randomized clinical trial, involving 2760 adults (≥18 years), in 41 UK National Health Service (NHS) intensive care units, requiring critical care within 24 hours of initiating intravenous antibiotics for suspected sepsis and likely to continue antibiotics for at least 72 hours.
Intervention
From January 1, 2018, to June 5, 2024, 918 patients were assigned to the daily PCT-guided protocol, 924 to the daily CRP-guided protocol, and 918 assigned to standard care. Main Outcomes and Measures The primary outcomes were total duration of antibiotics (effectiveness) and all-cause mortality (safety) to 28 days. Secondary outcomes included critical care unit data and hospital stay data. Ninety-day all-cause mortality was also collected.
Results
Among the randomized patients (mean age 60.2 [SD, 15.4] years; 60.3% males), there was a significant reduction in antibiotic duration from randomization to 28 days for those in the daily PCT-guided protocol compared with standard care (mean duration, 10.7 [SD, 7.6] days for standard care and 9.8 [SD, 7.2] days for PCT; mean difference, 0.88 days; 95% CI, 0.19 to 1.58, P = .01). For all-cause mortality up to 28 days, the daily PCT-guided protocol was noninferior to standard care, where the noninferiority margin was set at 5.4% (19.4% [170 of 878] of patients receiving standard care; 20.9% [184 of 879], PCT; absolute difference, 1.57; 95% CI, −2.18 to 5.32; P = .02). No difference was found in antibiotic duration for standard care vs daily CRP-guided protocol (mean duration, 10.6 [7.7] days for CRP; mean difference, 0.09; 95% CI, −0.60 to 0.79; P = .79). For all-cause mortality, the daily CRP-guided protocol was inconclusive compared with standard care (21.1% [184 of 874] for CRP; absolute difference, 1.69; 95% CI, −2.07 to 5.45; P = .03). Conclusions and Relevance Care guided by measurement of PCT reduces antibiotic duration safely compared with standard care, but CRP does not. All-cause mortality for CRP was inconclusive. Trial Registration isrctn.org Identifier: ISRCTN47473244
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Critical Care Unit, Northern Care Alliance NHS Foundation Trust, Salford Care Organization, Greater Manchester, United Ki…
- Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, United Kingdom.
- Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, United Kingdom.
- Royal Victoria Hospital Belfast, Belfast, United Kingdom.
- University College London Hospitals NHS Foundation Trust, United Kingdom.
- National Intestinal Failure Centre, Northern Care Alliance NHS Foundation Trust, Salford Care Organization, Greater Manchester, United Kingdom.
Zitieren
APA
Dark, P., Hossain, A., McAuley, D. F., Brealey, D., Carlson, G., Clayton, J. C., Felton, T. W., Ghuman, B. K., Gordon, A. C., Hellyer, T. P., Lone, N. I., Manazar, U., Richards, G., McCullagh, I. J., McMullan, R., McNamee, J. J., McNeil, H. C., Mouncey, P. R., Naisbitt, M. J., …, & ADAPT-Sepsis Collaborators (2025). Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis. JAMA, 333(8), 682. https://doi.org/10.1001/jama.2024.26458
Vancouver
Dark P, Hossain A, McAuley DF, Brealey D, Carlson G, Clayton JC, et al. Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis. JAMA. 2025;333(8):682. doi:10.1001/jama.2024.26458
BibTeX
@article{Dark2025,
author = {Dark, Paul and Hossain, Anower and McAuley, Daniel F and Brealey, David and Carlson, Gordon and Clayton, Jonathan C and Felton, Timothy W and Ghuman, Belinder K and Gordon, Anthony C and Hellyer, Thomas P and Lone, Nazir I and Manazar, Uzma and Richards, Gillian and McCullagh, Iain J and McMullan, Ronan and McNamee, James J and McNeil, Hannah C and Mouncey, Paul R and Naisbitt, Micheal J and Parker, Robert J and Poole, Ruth L and Rostron, Anthony J and Singer, Mervyn and Stevenson, Matt D and Walsh, Tim S and Welters, Ingeborg D and Whitehouse, Tony and Whiteley, Simon and Wilson, Peter and Young, Keith K and Perkins, Gavin D and Lall, Ranjit and ADAPT-Sepsis Collaborators, ADAPT-Sepsis Collaborators},
title = {Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis},
journal = {JAMA},
year = {2025},
volume = {333},
number = {8},
pages = {682},
doi = {10.1001/jama.2024.26458}
}
EUVIMED